Tonix Pharmaceuticals Holding Corp. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Cover
- Cover
Financial Statements
Notes to Financial Statements
Accounting Policies
- SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

LICENSE AGREEMENTS WITH UNIVERSITY OF MASSACHUSETTS (UMASS)

LICENSE AGREEMENTS WITH UNIVERSITY OF MASSACHUSETTS (UMASS)	12 Months Ended
Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]
LICENSE AGREEMENTS WITH UNIVERSITY OF MASSACHUSETTS (UMASS)	NOTE 12 – LICENSE AGREEMENTS WITH UNIVERSITY OF MASSACHUSETTS (UMASS) On June 26, 2025, Tonix obtained an exclusive worldwide license from UMass Chan Medical School for the development of TNX-4800 (formerly known as mAb 2217LS). As of December 31, 2025, other than the upfront fee of $1.3 million, no payments have been accrued or paid in relation to this agreement.

LICENSE AGREEMENTS WITH UNIVERSITY OF MASSACHUSETTS (UMASS)

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

LICENSE AGREEMENTS WITH UNIVERSITY OF MASSACHUSETTS (UMASS)

NOTE 12 – LICENSE AGREEMENTS WITH UNIVERSITY OF MASSACHUSETTS (UMASS)

On June 26, 2025, Tonix obtained an exclusive worldwide license from UMass Chan Medical School for the development of TNX-4800 (formerly known as mAb 2217LS). As of December 31, 2025, other than the upfront fee of $1.3 million, no payments have been accrued or paid in relation to this agreement.